Sumitomo Pharma raised FY24 operating loss guidance by ¥199B to ¥355B due to impairment loss. The company expects to turn profitable in FY25 via cost cutting. The company suspends FY25 dividend.
What is covered in the Full Insight:
Revised FY24 and FY25 Guidance
Impairment Loss and Business Structure Improvement Expenses
Potential New Cancer Drugs
Sumitomo's Struggle Post-Latuda Success
Investment Risks Borne by Poor Long-term Growth
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.